Key result
Admission TAPSE/PASP >0.47 linked to ~42% lower risk of 1-year death or HF hospitalization.
Why the study?
The role of TAPSE/PASP, a measurement of right ventricular to pulmonary artery coupling, was poorly described in patients hospitalized for acute heart failure.
Does the TAPSE/PASP ratio on admission predict 1-year all-cause death or heart failure hospitalization in patients hospitalized for acute heart failure?
Cohort (n=340)
No
Does the TAPSE/PASP ratio on admission predict 1-year all-cause death or heart failure hospitalization in patients hospitalized for acute heart failure?
Hazard Ratio: 0.582 (95% CI 0.355–0.955)
p-value: p=0.032
The TAPSE/PASP ratio on admission is an independent prognostic marker for 1-year mortality and heart failure hospitalization in patients with acute heart failure.
Supports admission TAPSE/PASP for risk stratification in acute HF; leaves open its role in guiding therapy.
BACKGROUND: The role of TAPSE/PASP, a measurement of right ventricular to pulmonary artery coupling, in patients hospitalized for acute heart failure (AHF) is poorly described. OBJECTIVES: To evaluate the prognostic impact of TAPSE/PASP in AHF. METHODS: This retrospective single-center study included patients hospitalized for AHF between January 2004 and May 2017. TAPSE/PASP was evaluated as a continuous variable and as tertiles according to its value on admission. The main outcome was the composite of 1-year all-cause death or heart failure hospitalization. RESULTS: A total of 340 patients were included [mean age 68.8 ± 11.8 years; 76.2% men, mean left ventricular ejection fraction (LVEF) 30.4 ± 13.3%]. Patients with lower TAPSE/PASP had more comorbidities and a more advanced clinical profile, and received higher doses of intravenous furosemide in the first 24 h. There was a significant, linear, inverse relationship between TAPSE/PASP values and the incidence of the main outcome (P = 0.003). In two multivariable analyses including clinical (model 1), biochemical and imaging parameters (model 2) TAPSE/PASP ratio was independently associated with the primary end point [model 1: hazard ratio 0.813, 95% confidence interval (CI) 0.708-0.932, P = 0.003; model 2: hazard ratio 0.879, 95% CI 0.775-0.996, P = 0.043]. Patients with TAPSE/PASP greater than 0.47 mm/mmHg had a significantly lower risk of the primary end point (model 1: hazard ratio 0.473, 95% CI 0.277-0.808, P = 0.006; model 2: hazard ratio 0.582, 95% CI 0.355-0.955, P = 0.032; both compared with TAPSE/PASP <0.34 mm/mmHg). Similar findings were observed for 1-year all-cause mortality. CONCLUSION: TAPSE/PASP on admission demonstrated a prognostic value among patients with AHF.
No takes yet. Share an insight, caveat, or question.
Bonelli et al. (2023) conducted a cohort in Acute heart failure (n=340). TAPSE/PASP >0.47 mm/mmHg vs. TAPSE/PASP <0.34 mm/mmHg was evaluated on Composite of 1-year all-cause death or heart failure hospitalization (HR 0.582, 95% CI 0.355-0.955, p=0.032). A TAPSE/PASP ratio >0.47 mm/mmHg on admission was associated with a lower risk of 1-year death or heart failure hospitalization compared to <0.34 mm/mmHg (HR 0.582; 95% CI 0.355-0.955; P=0.032).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: